Mark joined Charnwood Molecular as Chief Commercial Officer in June 2021. He has extensive experience growing discovery and development service businesses.

Mark has held a number of board roles before joining Charnwood, most recently as CCO of Arcinova, prior to its acquisition by Quotient Sciences. At Arcinova, Mark and his team significantly expanded the customer base and more than quadrupled sales over a 5-year period. Previous roles include CEO of Physiomics PLC, an AIM-listed oncology in silico modelling company and VP of business development at Excelsyn, prior to its acquisition by AMRI. Earlier in his career, Mark also spent several years in senior roles at BioFocus, a discovery services and drug development business, prior to its acquisition by Galapagos NV.

Qualifications.

Mark holds an MBA with distinction from Imperial College London, a PhD in Molecular Biology from Newcastle University and a 1st class honours degree in Genetics from The University of Nottingham.

Specialisms.

Mark is an expert in expanding the customer base of drug discovery and development providers and delivering profitable sales growth through an unwavering customer focus.